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Due to their widespread diffusion, perfluoroalkyl substances (PFASs) have been frequently found in the en-
vironment and in several animal species. It has been demonstrated that they can easily reach also humans,
mainly through diet. Being lactation a major route of elimination of these contaminants, their occurrence
in human milk is of particular interest, especially considering that it generally represents the unique food
source for newborns. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), the two most im-
portant compounds of this family, have been frequently found in human milk at variable concentrations, but
still limited data are available. The present study, the first conducted in Italy capable to detect these pollut-
ants at ultra-trace levels by UPLC-MS/MS, confirmed the role of lactation as a relevant source of exposure
for breastfed children. The measured concentrations ranged between 15 and 288 ng/L for PFOS and between
24 and 241 ng/L for PFOA. Moreover, mean concentrations and frequencies of both analytes resulted higher in
milk samples provided by primiparous women, suggesting that the risk of intakemight be higher for first-borns.
Finally, comparing these results with previous data, PFOS gradual decrease over time since year 2000 was
confirmed.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Perfluoroalkyl substances (PFASs) is the name of a wide group of
synthetic substances that, due to their physicochemical properties,
have been largely employed during the last 60 years in multiple com-
mon use products. The extensive use of these compounds led to their
global distribution as persistent contaminant into the environment,
including animals and humans, and even in regions far from anthro-
pogenic activities (EFSA, 2008; Prevedouros et al., 2005). Several
studies highlighted the bioaccumulation potential of certain PFASs,
as perfluorinated sulfonates and long-chain (>7 fluorinated carbons)
perfluorinated carboxylates, even if further investigations are needed
to fully understand the behavior of the different types of compounds
(Conder et al., 2008). Because of their amphiphilic properties, un-
like other persistent halogenated compounds which accumulate
in fatty tissues, PFASs bind to proteins and have been frequently
found in human plasma: diet is considered the main exposure
route for the population, especially through seafood consumption,
but other high protein content food categories, including milk, eggs
and meat, might also represent a risk (EFSA, 2011). The effects of
these substances on human health haven't been fully ascertained
yet, but they seem to be related to a wide range of pathologies in
the exposed organisms, such as hepatotoxicity, neurobehavioral
toxicity, immunotoxicity, lung toxicity, reproductive toxicity and
hormonal effects (OECD, 2002).
Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid
(PFOA) are the twomost studied and frequently foundmolecules be-
longing to this family. Their half-life in humans has been estimated
to be of more than 5 years for PFOS and around 4 years for PFOA
(Olsen et al., 2007).
Due to their high persistency in the environment, tendency to
bioaccumulate in organisms and potentially dangerous effects on
human health, PFOS and its salts have been recently included as per-
sistent organic pollutant (POP) in Annex B of the 2009 Stockholm
Convention and their manufacturing and use have been restricted
(Wang et al., 2009).
The ability of PFOS and PFOA to cross the placental barrier and to
be eliminated through lactation has been observed in multiple animal
species and recently confirmed in humans as well (Midasch et al.,
2007; Völkel et al., 2008). Studies on rodents showed that prenatal
exposure to these chemicals delays development and reduces surviv-
al and weight gain (Lau et al., 2007). The potential toxicity of PFASs in
human fetuses and in newborns raised the interest of the scientific
community on their occurrence in breast milk, since this latter repre-
sents in most cases the sole food source during the first year of life.
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Several studies evaluated the occurrence of these pollutants in human
milk in different countries, detecting PFOS and PFOA in almost every
sample (Fromme et al., 2009). In addition, up to now no data from
Italy are available.
In this context, the aims of the present work were: 1) to perform a
survey on the presence of perfluoroalkyl chemicals in human milk
from Italy, in order to overcome the lack of information concerning
this country and contributing at the same time to the collection of
useful data for risk assessment on breastfed children's exposure to
these emerging contaminants; 2) to assess potential correlations be-
tween the primipara/multipara status of the donor and measured
levels of PFOS and PFOA.
2. Material and methods
2.1. Reagents and chemicals
Perfluoro-n-octanoic acid (PFOA), sodium perfluoro-1-
octanesulfonate (PFOS) and their relative 13C-labeled internal stan-
dards (purity greater than 98%) were purchased fromWellington Labo-
ratories (Guelph, Ontario, Canada). Methanol and ammonium acetate
were of LC–MS grade and were both acquired from Fluka (Sigma
Aldrich, St. Louis, MO, USA); acetone was from VWR (Radnor, PA,
USA), while glacial acetic acid, formic acid and ammonia solution
(33%) were from Sigma Aldrich (St. Louis, MO, USA). Ultrapure water
was produced in-house with a Human Power I system (Seoul, Korea).
Oasis®HLB500 mgSPE cartridgeswere purchased fromWaters (Milford,
MA, USA), while Envicarb® 500 mg SPE cartridges were from Supelco
(Sigma Aldrich, St. Louis, MO, USA).
2.2. Sample collection
All the breast milk samples were provided by the Department of
Paediatrics of the Sant'Orsola-Malpighi Hospital of Bologna, with the
authorization of the Independent Ethics Committee of the hospital
(clinical trial # 49/2011/U/Tess). Among the 37 samples, collected
during the second semester 2010, 21 were from primipara donors
and 16 from women nursing for at least the second time. Collected
samples were transferred to polypropylene tubes and stored in the
dark at −20 °C.
2.3. Sample preparation
Samples were prepared following the extraction procedure de-
scribed by Kadar et al. (2011). First of all 3 mL of milk was transferred
into a polypropylene tube and spiked with the two internal standards,
then 9 mL of acetone was added to perform protein precipitation.
After being shaken for 30 s, the sample was placed for 10 min in an ul-
trasonic bath to facilitate the extraction and centrifuged at 2000×g for
10 min at room temperature. The supernatant was transferred to a
new polypropylene tube and evaporated to around 3 mL under gentle
nitrogen stream at 45 °C, then 8 mL of 0.1 M formic acid solution was
added in order to adjust the pH for the first purification step on the
Oasis® HLB cartridge. After conditioning the cartridge with 10 mL of
methanol and 10 mL of 0.1 M formic acid, always avoiding the solid
phase to go dry, the samplewas loaded. Once all the solution had passed
through the column, twowashings were performedwith 5 mL of 0.1 M
formic acid and with 5 mL of 0.1 M formic acid/methanol (50/50, v/v)
solution, then vacuumwas applied for 5 min to remove eventual residu-
al drops. The analytes were eluted with 6 mL of a mixture of methanol/
ammonia solution 33% (99/1, v/v) and subsequently concentrated to
around 2 mL under nitrogen. A second purification was achieved using
a Supelclean™ ENVI-Carb™ cartridge, previously activated with 10 mL
of methanol. After placing a new tube under the column, the sample
was loaded and then an elution with 6 mL of a methanol/glacial acetic
acid (80/1, v/v) solution was performed. The eluate was evaporated to
dryness under nitrogen and reconstituted in 200 μL of methanol/water
(50/50, v/v) solution. The content of the tube was transferred into a
microtube and centrifuged at 12,000 rpm for 45 min, then 150 μL was
collected and added to 50 μL of water in a polypropylene vial prior to
analysis in UPLC–MS/MS.
2.4. UPLC–MS/MS analysis
Analysis was performed on an UPLC–MS/MS system, including a
Waters Acquity UPLC® binary pump, equipped with built-in vacuum
degasser, thermostated autosampler and column heater. Chromato-
graphic separation was achieved using a Waters Acquity UPLC® BEH
C18 reversed-phase column (50×2.1 mm, 1.7 μm),fittedwith aWaters
VanGuard guard columnwith the samepackaging (Waters Corporation,
Milford, MA, USA). The mobile phase consisted of ammonium acetate
20 mM aqueous solution (solvent A) and methanol (solvent B). The
gradient (constant flow rate at 0.5 mL/min) started with 30 s at 70% A
and 30% B, then switched to 100% B over 1 min and held for 1.5 min,
thenwent back to the initial conditions in 0.5 min and held for a further
1.5 min, in order to equilibrate the column before the following injec-
tion. Samples were kept at 6 °C in the autosampler and 10 μL was
injected in “full loop”mode; the column was kept at 45 °C to avoid ex-
cessive backpressures.
The chromatographerwas interfacedwith aWaters Quattro Premier
XE tandemmass spectrometer, equippedwith an ESCi multi-mode ion-
ization source (Waters Corporation, Milford, MA, USA) and operating in
negative electrospray ionization (ESI−) mode. Analysis was performed
in MRM (multiple reaction monitoring) mode, following two transi-
tions for PFOS and PFOA and one for each internal standard: the selected
values of cone voltage, collision energy and transitions are reported in
Table 1. The following parameters were applied: capillary voltage was
set at 2.00 kV and cone voltage at 3.00 V, while source and desolvation
temperatures were 150 and 220 °C, respectively. Nitrogen flowwas set
at 50 L/h on the cone and 700 L/h for desolvation; argon was used as
collision gas at 0.35 mL/min. Data acquisition and processing were
performed using MassLynx 4.1 software (Waters Corporation, Milford,
MA, USA).
The presence of potential background contaminations was prevented
by instrumental analysis of the employed solvents, performed at the be-
ginning of the experiment in order to assess the absence of signals corre-
sponding to our target analytes, and constantly monitored through the
injection of a mobile phase sample every five milk samples during each
analysis session.
2.5. Method validation
The method was validated in accordance with current European
guidelines set by 2002/657/EC, employing selected cow milk samples
Table 1
Monitored transitions and their relative specific parameters.
Analyte Transition 1 (m/z) Cone voltage (V) Collision energy (eV) Transition 2 (m/z) Cone voltage (V) Collision energy (eV)
PFOA 412.8>369.0 12 10 412.8>169.0 12 17
PFOS 498.6>498.6 52 10 498.6>80.0 52 43
13C PFOA 416.9>372.0 11 10
13C PFOS 502.86>80.0 50 11
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which had been proved to be non-contaminated by target analytes,
since no blank breast milk was available. A six point (range 0–
2000 ng/L) matrix-matched calibration curve was prepared each day of
analysis, proving the method's linearity: the coefficient of determination
R2 was always greater than 0.99 and relative standard deviations were
lower than 17%. Specificitywas assessed excluding the presence of poten-
tial interferences aroundPFOS andPFOA retention times in the chromato-
grams of non-contaminated samples. The injection of four replicates of
blank milk spiked at four different levels (50, 200, 400 and 800 ng/L)
demonstrated satisfying precision, with maximum relative standard de-
viations to the mean (CV%) of 8%, as well as good trueness values,
expressed as relative difference between the mean value measured and
the spiked concentration, resulting at always below10%. Limits of quanti-
fication (LOQs) of the method, defined as the concentrations providing a
chromatographic signal with a signal-to-noise (S/N) ratio equal to 10,
were 15 ng/L for PFOS and 24 ng/L for PFOA.
3. Results and discussion
All the samples resulted contaminated by the investigated com-
pounds. PFOS and PFOA were present at trace levels (lower than the
LOQ) in 22 and 24% of samples, respectively. In more detail, PFOS
was quantified in 90% of the samples provided by primiparous
mothers and in 62% of samples given by multiparas. Concentrations
ranged from 15 to 288 ng/L, with mean values of 57 ng/L, in the
case of mothers lactating for the first time and from 15 to 116 ng/L
(mean 36 ng/L) in the case of women who had already breastfed pre-
viously. Concerning PFOA, quantifiable levels were observed in 81% of
cases in primiparas and 46% of cases in multiparas, with concentra-
tions between 24 and 241 ng/L (mean 76 ng/L) and 24 and 100 ng/
L (43 ng/L), respectively (see Table 2 and Fig. 1).
The highest values were obtained for both PFOS (288 ng/L) and
PFOA (241 ng/L) in samples which had been provided by primiparous
women.
This survey was the first conducted in Italy on the presence of
perfluoroalkyl substances in breast milk capable of detecting ultra-
trace concentrations. The obtained data are in line with those reported
in similar studies performed in other developed countries, such as
France (Kadar et al., 2011), Germany (Bernsmann and Fürst, 2008;
Fromme et al., 2010; Völkel et al., 2008), Sweden (Kärrman et al.,
2007), Spain (Llorca et al., 2010), Hungary (Völkel et al., 2008), USA
(Tao et al., 2008a), Japan (Nakata et al., 2007; Tao et al., 2008b) and
China (Liu et al., 2010; So et al., 2006). In some of these works other
PFCs were also investigated, but PFOS always resulted as the most
found contaminant, being present in almost all the analyzed samples.
Moreover, considering PFOSmedian concentration for eachmonitoring
and taking into account the relative approximate time period of collec-
tion, a slight decrease of the measured values over time can be noticed.
In more detail, in the most recent surveys (from year 2010 onwards)
the median was lower than 100 ng/L (76 ng/L in the present one),
while the older works (up to year 2008) reported values generally
greater than 100 ng/L and up to over 300 ng/L. The presented data are
therefore consistent with the latest results from other developed coun-
tries, confirming the gradual decrease of this contaminant over time
since year 2000 in consequence of the almost complete end of its
manufacturing, as highlighted in a temporal trend study recently
conducted in Sweden (Sündstrom et al., 2011).
PFOA has been measured at levels generally slightly lower than
PFOS, but with a relevant variability in terms of frequency among
the various studies, which is likely to be partially related to the high
variability of the limits of quantification. In particular, the good sensi-
tivity of the equipment used in the present research allowed us to de-
termine this substance in all the analyzed samples, even at extremely
low concentrations.
PFASs levels in blood are significantly higher than in breastmilk, how-
ever their transfer from the former to the latter during breastfeeding has
been confirmed and the existence of correlations between measured
values in the two media has been proved (Fromme et al., 2010).
Taking into account the primipara/multipara status of this study's
donors, it was observed that the mean concentration and frequency
were higher for both the monitored analytes in milk provided by
women nursing for the first time. In particular, the mean measured
Fig. 1. PFOS and PFOA in breast milk samples of primiparous women (PW) and multip-
arous women (MW). Dashed line indicates the limit of quantification that was 15 ng/L
for PFOS and 24 ng/L for PFOA.
Table 2
Summary of the results of human milk sample analysis.
No of samples SamplesbLOQ Lowest conc. (ng/L) Highest conc. (ng/L) Mean conc.±SEMa (ng/L)
PFOA Primiparas 21 4 24 241 76±14
Multiparas 16 5 24 100 43±6
PFOS Primiparas 21 2 15 288 57±13
Multiparas 16 6 15 116 36±7
a SEM: standard error of mean.
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level of PFOS was 57 ng/L in samples from primiparas and 36 ng/L in
those from multiparous women, and for PFOA, this value decreased
from 76 to 43 ng/L. Therefore, although the number of processed sam-
ples is rather low to draw statistically significant conclusions, a trend for
both compounds to decrease in breast milk after the first lactation can
be noticed, as previously reported by Tao et al. (2008a) in a similar co-
hort of patients. On the one hand this confirms the role of breastfeeding
as a route of gradual elimination of perfluoroalkyl substances, while on
the other hand it suggests a potentially higher exposure to these con-
taminants for first-born infants. However, as recently reported by
Whitworth et al. (2012), it seems likely that the amount of PFASs
body burden among parous women is significantly influenced by the
length of the interpregnancy interval, meaning that, in case of extended
elapsed time since the previous birth, breast milk contamination may
get close to that of the first lactation.
Given all these outcomes, further investigations would be useful
to better understand the importance of infant exposure to PFASs
and identify potential influencing factors, especially considering the
fact that breast milk represents almost the entire diet for children
during the first months of life.
4. Conclusions
Data on the worldwide burden of the presence of these emerging
contaminants in human breast milk are limited: this study provides a
first picture of the situation in Italy, which resulted in contributing to
PFASs exposure risk assessment for infants. In particular, the role of
lactation as a source of both PFOS and PFOA for newborns was con-
firmed, suggesting a higher risk of exposure for first-born children
as a consequence of the accumulation of these chemicals in maternal
body during the lifetime until the first nursing, although it has been
hypothesized that a long interval between pregnancies may allow
the mother's body burden to significantly increase again.
The results of this preliminary monitoring, as well as the data
available from recent studies performed in other developed countries,
suggest that the toxicological risk related to the intake of these
emerging pollutants through breastfeeding is moderate and is appar-
ently decreasing with time. However, it must be considered that
breast milk represents almost the entire diet for one of the most sen-
sitive group of population, small children; moreover, a certain vari-
ability in the measured levels can be observed from country to
country and still no data are available from several regions all around
the globe. All these aspects highlight the need for further investiga-
tions on the existence of potential correlations between PFASs levels
in breast milk and mother's history, taking into account, besides age
at delivery and interpregnancy interval, also other possible influenc-
ing factors, such as length of breastfeeding, place of origin and diet
habits, in order to better define the real exposure for newborns.
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